ORMP: Broadening IP Protection, Positive Physician Indicators & Studies Advancing
By M. Marin
NASDAQ:ORMP
READ THE FULL ORMP RESEARCH REPORT
Broadening patent IP protection…
Oramed Pharma Shares Rebound From Session Low On Volume; Traders Circulate Zack’s Small Cap Research Note From Wednesday Showing $38 Valuation Target
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_04272022_ORMP_Marin.pdf
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Oramed Granted NASH Patent In Europe
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office has granted the Company
Oramed Pharma Reports Completion Of Patient Enrollment In Phase 2 Oral Insulin NASH Trial; Topline Results Expected H2’22
- Topline results expected H2 2022
- ORMD-0801 is the first oral insulin to be evaluated as a treatment for NASH
- Currently no FDA approved therapy exists for NASH
NEW YORK, March 16, 2022 /PRNewswire/ -- Oramed
52 Biggest Movers From Yesterday
Gainers
ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969.
Oramed Issues Annual Message To Shareholders
- Oral insulin program continues to advance with topline efficacy data expected in H2 2022
- Significant value creation opportunities through oral COVID-19 vaccine program and partnerships
- Well positioned to capitalize
Oramed Granted Key European Patent For Platform Technology In Oral Delivery Of Proteins
- Protease inhibitor is a key component of Oramed's PODTM technology that protects therapeutic proteins in the digestive system
- Oramed has already been granted this patent in the United States and Japan
NEW YORK,